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Abstract
Background: Rising prostate-specific antigen (PSA) levels after radical therapy are indicative
of recurrent or residual prostate cancer (PCa). This biochemical recurrence typically predates
clinically detectable metastatic disease by several years. Management of patients with
biochemical recurrence is controversial.
Objective: To assess the effect of dutasteride on progression of PCa in patients with biochemi-
cal failure after radical therapy.
Design, setting, and participants: Randomised, double-blind, placebo-controlled trial in
294 men from 64 centres across 9 European countries.
Intervention: The 5a-reductase inhibitor, dutasteride.
Outcome measurements and statistical analysis: The primary end point was time to PSA
doubling from start of randomised treatment, analysed by log-rank test stratified by previous
therapy and investigative-site cluster. Secondary end points included time to disease progres-
sion and the proportion of subjects with disease progression.
Results and limitations: Of the 294 subjects randomised (147 in each treatment group), 187
(64%) completed 24mo of treatment and 107 discontinued treatment prematurely (71 [48%] of
the placebo group, 36 [24%] of the dutasteride group). Dutasteride significantly delayed the
time to PSA doubling comparedwith placebo after 24mo of treatment ( p < 0.001); the relative
risk (RR) reduction was 66.1% (95% confidence interval [CI], 50.35–76.90) for the overall study
period. Dutasteride also significantly delayed disease progression (which included PSA- and
non-PSA-related outcomes) compared with placebo ( p < 0.001); the overall RR reduction in
favour of dutasteride was 59% (95% CI, 32.53–75.09). The incidence of adverse events (AEs),
ading to study withdrawal were similar between the treatment groups.
investigators were not blinded to PSA levels during the study.
ide delayed the biochemical progression of PCa in patients with bio-serious AEs, and AEs le
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Increasing adoption of prostate-specific antigen (PSA)
testing has led to a migration in the stage and grade of
prostate cancer (PCa) at diagnosis such that most affected
men present with localised disease [1]. While most patients
with clinically localised disease undergo radical prostatec-
tomy (RP) or radiotherapy (RT), local or distant recurrences
develop in up to half of intermediate- or high-risk patients
within 10 yr [2].
Elevated or rising PSA level after radical therapy is
indicative of recurrent or residual PCa. This biochemical
recurrence typically predates clinically detectable meta-
static disease by several years [3]. European Association of
Urology (EAU) guidelines recommend watchful waiting
with possible delayed androgen-deprivation therapy (ADT),
or salvage RT, in patients with presumed local failure after
RP [2]. A similar approach is recommended for patientswith
presumed local failure after RT. Nevertheless, the manage-
ment of these patients is complex and controversial [4].
The Avodart After Radical Therapy for Prostate Cancer
Study (ARTS) assessed the effect of dutasteride (Avodart;
GlaxoSmithKline plc, Brentford, Middlesex, UK) on PCa
progression in patients with biochemical failure after
radical therapy [4]. In this paper, we report the key efficacy
and safety findings from the study.
2. Patients and methods
This was a 2-yr, multicentre, randomised, double-blind, placebo-
controlled trial. Eligible men were <85 yr of age with asymptomatic
PSA failure following radical therapy with curative intent for clinically
localised PCa. Definitions of PSA failure were based on the recommenda-
tions from the EAUguidelines onPCa (for subjects treatedwithRP) or from
the Radiation Therapy Oncology Group–American Society for Therapeutic
Radiology and Oncology 2005 Consensus Conference (for subjects treated
with RT) [2,5]. Additional entry criteria included serum PSA levels of
2–20 ng/ml for men treated with primary RT or 0.4–10 ng/ml for men
treated with RP with or without salvage RT; PSA doubling time (PSADT)
>3 mo and 24 mo; clinical stage T1–T3a N0 M0; nonmetastatic PCa as
confirmed on negative bone scan within 6 mo prior to randomisation; no
evidenceof local recurrence inRPor salvageRT subjects; expected survival
2yr;andEasternCooperativeOncologyGroupperformancestatus0,1,or
2. Sixty-four centres in nine European countries (Estonia, France, Finland,
Germany, The Netherlands, Russia, Spain, Sweden, and the United
Kingdom) randomised at least one subject.
Independent ethics committees approved the protocol and the trial
was conducted in accordance with the Declaration of Helsinki, the
International Conference on Harmonisation Good Clinical Practice, and
any applicable local regulations. All patients provided written informed
consent prior to study initiation. The study is registered with
ClinicalTrials.gov (NCT00558363).
2.1. Randomisation and masking
Eligible subjects were randomised 1:1 to receive dutasteride 0.5 mg or
placebo once daily for 2 yr. Randomisation to treatment groups was
performed in blocks, stratified by previous therapy (RP with or without
salvage RT or primary RT) and by centre. GlaxoSmithKline and site
personnel, including participants, were masked to study treatment
allocation until the study conduct was finished and the database was
frozen.2.2. Outcome measures
The primary efficacy assessment was the number of days between start
of treatment and the first instance of PSA value being at least twice the
latest PSA value before the start of treatment (baseline), followed by
confirmation in the immediate, subsequent PSA evaluation when
available. Subjects who did not have PSA doubling were censored at
the last postbaseline PSA evaluation. PSA evaluations during the study
were performed by a central laboratory.
Secondary efficacy assessments included time to disease progression
and the proportion of subjects with disease progression, with time to
disease progression defined as the number of days between the start of
treatment and the earliest of any of the following: PSADT 3 mo, or PSA
>20 ng/ml (subjects who underwent primary RT) or>10 ng/ml (subjects
who underwent RP with or without salvage RT) associated with 50%
increase from baseline PSA and confirmed in an immediate, subsequent
PSA determination if available; any biopsy-confirmed progression in the
clinical stage (T stage); need for additional PCa rescue therapy;
metastatic disease confirmed by bone scan (bone scans were performed
at 24mo, or at thewithdrawal visit if applicable, to evaluate the presence
of any bone metastases). Subjects who did not have disease progression
were censored at the earliest of these dates: the last postbaseline PSA
evaluation date; date of last postbaseline bone scan with no metastases;
date of last postbaseline ad hoc biopsy with no positive core; last date of
successful phone contact during which surgical and nonsurgical
intervention were confirmed as none.
Additional secondary efficacy assessments were percentage of
subjects with a treatment response (either a PSA decrease or an
increase 15% from baseline to 24 mo of treatment confirmed in all
PSA measurements); time to PSA rise from baseline and the proportion
of subjects with a PSA rise from baseline, defined as first PSA value
showing a >15% increase from baseline confirmed in all subsequent
measurements; time to PSA progression and percentage of subjects
with PSA progression based on the definition of a subject experiencing
PSADT 3 mo or PSA >20 ng/ml (subjects who underwent primary RT)
or PSA >10 ng/ml (subjects who underwent RP with or without
salvage RT) associated with 50% increase from the baseline PSA
measurement and confirmed in an immediate subsequent PSA level
determination. Subjects without PSA rise or PSA progression were
censored at the last postbaseline PSA evaluation.
Safety assessments included changes on physical examination,
adverse events (AEs), vital signs measurements, and laboratory tests.
All subjects had PSA level monitored every 3 mo during the treatment
phase and then at the follow-up visit (4 mo after the end of treatment).
2.3. Statistical methods
Given a median time to PSA doubling of 10 to 11 mo for the placebo
group [6,7] and assuming 31.8% of the dutasteride subjects had a PSA
doubling at this time point (hazard ratio: 0.605), 110 subjects per
treatment arm were required to provide 80% power to show superiority
of dutasteride over placebo using a two-sided log-rank test at a = 0.05.
Assuming a 20% withdrawal during the study, approximately
138 subjects per treatment arm were needed to be randomised, for a
total of 276 subjects.
The primary population for analysis was the intention-to-treat (ITT)
population, which included all subjects randomised to study treatment.
PSA-related end points considered only the PSA values that might be
considered related to the study drug, as restricted by PSA limit date
(defined by the latest end-of-treatment visit or laboratory evaluation
date and the study drug stop date). PSA evaluations after the PSA limit
date were excluded from analysis.
The primary end point was analysed using a log-rank test stratified
by previous therapy and investigative-site cluster (defined as a cluster of
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compared using a Mantel-Haenszel test, with the analysis repeated and
stratified by previous radical therapy, and was also summarised by
subgroups of interest (eg, baseline PSADT <12 mo and 12 mo).
The influence of subject characteristics at study baseline or at first
PCa diagnosis on time to PSA doubling was assessed using a Cox
proportional hazard regression model. Baseline characteristics consid-
ered in the model were age, previous radical therapy, time to screening
from radical therapy, baseline PSA, and baseline PSADT. Additional
factors considered were last PSA value before radical therapy; Gleason
score (<7 or 7), T stage (T1c or >T1c), and risk score (low = 0,
medium = 1, high = 2) at diagnosis; and hormonal medication use.
Duration of previous hormone therapy (HT) for a subject was calculated
from the earliest start and latest stop dates of such therapies: when a
date was missing, the 15th of the month was imputed, but if month
and/or year were missing, the subject was not used in the calculation of
duration of HT.
The proportion of subjects with a treatment response was compared
between treatment groups using a Mantel-Haenszel test. Other
secondary end points were analysed in a similar way to the primary
end point.
AEs and changes in clinical laboratory values were evaluated using
the ITT population. Other safety measures included gynaecomastia
evaluations every 6 mo, and digital rectal examinations and vital signs
measurements every 12 mo. All summaries were provided by random-
ised treatment group.
3. Results
3.1. Participants
Of the 294 subjects randomised (147 in each treatment
group), 187 (64%) completed 24 mo of treatment and 107
discontinued prematurely (71 [48%] in the placebo group,
36 [24%] in the dutasteride group) (Fig. 1). The primary
reason for discontinuation in both treatment groups was
disease progression. Demographics and baseline character-
istics were generally similar in the two treatment groups
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Fig. 1 – Subject disposition. PSA(Table 1). Fifteen percent of patients (43 of 294) had
received previous HT (15% in the dutasteride group, 14% in
the placebo group). Mean duration of previous HT (from
21 subjects in each treatment group for which this
information is available)was 131 d (146 d in the dutasteride
group, 116 d in the placebo group). Mean time between
latest date of HT and screening was 1700 d (1576 d in the
dutasteride group, 1825 d in the placebo group). The
majority of subjects reported being sexually inactive (68% of
placebo group, 66% of dutasteride group) and also impotent
(73% of placebo group, 76% of dutasteride group) in the 3mo
before screening.
3.2. Primary end point
3.2.1. Overall population
Dutasteride significantly delayed the time to PSA doubling
compared with placebo after 24 mo of treatment
( p < 0.001). The relative risk (RR) reduction was 66.1%
(95% confidence interval [CI], 50.35–76.90) for the overall
study period. The Kaplan-Meier curves for time to PSA
doubling began to diverge from approximately month 6,
and the divergence between the two treatment groups
continued to increase through to month 24 (Fig. 2). The
incidence of PSA doubling over the 2-yr treatment period
(based on ITT subjects with at least one postbaseline PSA
evaluation) was 57% (82 of 144 subjects) in the placebo
group and 28% (41 of 146 subjects) in the dutasteride
group ( p < 0.001). The median follow-up time was 722 d
for the dutasteride group and 456 d for the placebo group
(Table 2).
The following baseline variables were associated with
time to PSA doubling by Cox proportional hazards regres-
sion modelling: type of radical therapy, baseline PSA value,
baseline PSADT, and time to screening from radical therapy.
Other associated factors were Gleason score and clinicalAt least one post-baseline PSA evaluation (n = 144)
Completed 24-mo treatment period (n = 76)
Prematurely withdrawn (n = 71)
Disease progression (n = 32)
Investigator decision (n = 18)
Subject decided to withdraw (n = 11)
Adverse event (n = 5)
Lack of efficacy (n = 2)
Protocol violation (n = 2)
Lost to follow-up (n = 0)
Other (n = 1)
Allocated to placebo (n = 147)
Received allocated intervention (n = 147)
n
up
d (n = 294)
= prostate-specific antigen.
Table 1 – Subject characteristics at screening/baseline in intention-to-treat population
Placebo (n = 147) Dutasteride (n = 147)
Region (site cluster), no. (%)
Spain 57 (39) 51 (35)
United Kingdom, The Netherlands, France, Germany 53 (36) 55 (37)
Estonia, Finland, Sweden, Russia 37 (25) 41 (28)
Previous therapy, no. (%)
Radical prostatectomy 119 (81) 114 (78)
With salvage therapy 29 23
Without salvage therapy 90 91
Primary radiotherapy 28 (19) 33 (22)
Sexual function, no. (%)
Inactive at screening 100/146 (68) 97/146 (66)
Impotence in the 3 mo before study entry 106/146 (73) 110/145 (76)
Age, yr, mean (SD, range) 68.6 (6.53, 52–81) 69.7 (5.76, 52–83)
Race, white, no. (%) 146 (>99) 147 (100)
Body mass index, kg/m2, mean (SD, range) 27.80 (3.761, 20.3–42.0) 27.53 (3.361, 20.9–39.6)
Baseline PSA <10 ng/mla, no. (%) 144 (98) 138 (94)
Baseline PSADT <12 moa, no. (%) 92 (63) 88/145 (61)
Time to screening from radical therapy >3 yr, no. (%) 101 (69) 99 (67)
Hormonal medication use before screening no. (%) 21 (14) 22 (15)
Gleason score <7 at diagnosisb, no. (%) 73/130 (56) 78/130 (60)
Clinical T stage >T1c at diagnosisb, no. (%) 98 (67) 97/146 (66)
Last PSA value before radical therapy <10 ng/mlb,c, no. (%) 82/145 (57) 84/144 (58)
Risk score, no. (%)
Low 34/146 (23) 48/146 (33)
Medium 77/146 (53) 65/146 (45)
High 35/146 (24) 33/146 (23)
SD = standard deviation; PSA = prostate-specific antigen; PSADT = PSA doubling time.
a Latest available value on or before treatment start.
b At time of prostate cancer diagnosis.
c Definitions based on Gleason score at diagnosis (<7, 7, or >7), clinical stage at diagnosis (<T2a, T2b-T2c, or >T2c), and last PSA before radical therapy (<10, 10–
20, or >20 ng/ml). Denominators represent the number of data points available when this is not the same as the population.
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Using these variables in the model, the RR reduction in
favour of dutasteride increased from 66% to 70%, supporting
a consistent treatment effect. The RR for PSA doubling was
higher for subjects with Gleason score 7 compared with
Gleason score <7, and for those with tumour stage >T1c
[(Fig._2)TD$FIG]
Fig. 2 – Kaplan-Meier estimates of time to prostate-specicomparedwith tumour stageT1c. The RR for PSA doubling
also increased with higher baseline PSA, lower baseline
PSADT, and less time between radical therapy and
screening. The RR was lower for primary RT subjects
compared with RP subjects and for those who used HT prior
to screening compared with those who did not.fic antigen doubling (intention-to-treat population).
Table 3 – Incidence of prostate-specific antigen doubling from
baseline by subgroups of interest
Placebo,
no. (%)
Dutasteride
0.5 mg, no. (%)
Subject characteristics at baseline
Age, yr
<65 25/37 (68) 8/21 (38)
65 57/107 (53) 33/125 (26)
Site cluster
Spain 33/56 (59) 15/51 (29)
United Kingdom, The Netherlands,
France, Germany
32/53 (60) 16/55 (29)
Scandinavia, Eastern European
Countries
17/35 (49) 10/40 (25)
Baseline PSA, ng/ml
<10 82/141 (58) 37/137 (27)
10–20 0/3 4/9 (44)
Baseline PSADT, mo
<12 55/89 (62) 30/88 (34)
12 27/55 (49) 10/56 (18)
Time from screening to radical therapy, yr
1 2/3 (67) 3/3 (100)
>1 to 2 14/20 (70) 5/17 (29)
>2 to 3 17/22 (77) 19/28 (68)
>3 49/99 (49) 14/98 (14)
Characteristics of prostate cancer at diagnosis and treatment prior
to baseline
Previous therapy
Radical prostatectomy 68/116 (59) 35/114 (31)
Primary radiotherapy 14/28 (50) 6/32 (19)
Gleason scorea
<7 33/72 (46) 19/78 (24)
7 40/57 (70) 20/51 (39)
Clinical T stageb
T1c 22/47 (47) 11/49 (22)
>T1c 60/97 (62) 30/96 (31)
Last PSA value before radical therapyc, ng/ml
<10 46/81 (57) 21/84 (25)
10–20 26/45 (58) 12/42 (29)
>20 10/17 (59) 6/17 (35)
Hormone therapy used before screening
Yes 10/19 (53) 5/21 (24)
No 72/125 (58) 36/125 (29)
Risk scored
Low 16/33 (48) 10/48 (21)
Medium 44/76 (58) 18/65 (28)
High 22/35 (63) 13/32 (41)
PSA = prostate-specific antigen; PSADT = prostate-specific antigen
doubling time.
a Gleason score from diagnostic biopsy.
b Clinical tumour stage provided by site as last available staging before
radical therapy.
c For subjects with radical prostatectomy (with or without salvage
radiotherapy), the latest available PSA value before prostatectomy was used.
For subjects with primary radiotherapy, the latest available PSA value before
the start of radiation therapy was used.
d Definitions are based on Gleason score at diagnosis (<7, 7, or >7), clinical
stage at diagnosis (<T2a, T2b-T2c, or >T2c), and last PSA value before radical
therapy (<10, 10–20, or >20 ng/ml).
Table 2 – Summary of prostate-specific antigen doubling in
intention-to-treat population
Placebo Dutasteride
Subjects with PSA doublinga, no. (%) 82/144 (57) 41/146 (28)
Total person-timeb, d 65 928 86 180
Person-timeb, d, median (range) 456 (53–771) 722 (22–805)
Rate of PSA doubling (cases per person-time)
Per day 0.0012 0.0005
Per year 0.45 0.17
PSA = prostate-specific antigen.
a Three placebo subjects and one dutasteride subject did not have
a postbaseline PSA measurement and so were not counted in the
denominator.
b Follow-up time was the number of days between the randomised-
treatment start date and either PSA-doubling date or censoring date.
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prespecified subgroups. Among those with baseline PSADT
<12 mo, the incidence of PSA doubling was 34% in the
dutasteride group and 62% in the placebo group.
3.2.2. Response by previous therapy
The benefit of dutasteride over placebo in delaying the time
to PSA doubling was observed both in subjects previously
treated with RP (p < 0.001; RR reduction: 64.65%; 95% CI,
46.64–76.58) and those previously treated with primary
RT ( p = 0.007; RR reduction: 73.94%; 95% CI, 25.83–90.84).
The incidence of PSA doubling over the 2-yr treatment
period was also significantly lower in the dutasteride group
than in the placebo group regardless of previous radical
therapy (RP: 31% [35 of 114] vs 59% [68 of 116], p < 0.001;
primary RT: 19% [6 of 32] vs 50% [14 of 28], p = 0.011).
3.3. Secondary end points
Dutasteride significantly delayed disease progression com-
pared with placebo ( p < 0.001); the overall RR reduction in
favour of dutasteride was 59% (95% CI, 32.53–75.09). The
Kaplan-Meier curves for time to disease progression began
to diverge from approximately month 6, and the divergence
between the two treatment groups continued to increase
through to month 24 (Fig. 3). The incidence of disease
progression was 17% (25 of 146) in the dutasteride group
and 34% (49 of 144) in the placebo group (p < 0.001). The
benefit of dutasteride over placebo for reducing the risk of
disease progression was observed across PSA-related
disease progression events as well as clinical-related
outcomes (Table 4). Fewer patients in the dutasteride
group required additional rescue therapy and fewer
developed bone metastases (nine subjects in the placebo
group and four in the dutasteride group had bone
metastases; five and two of these cases, respectively, were
preceded by another disease progression criterion).
Forty subjects had at least one intervention for PCa
during the study (29 subjects in the placebo group and 11 in
the dutasteride group) (Table 5); only 20 of these were
considered as having disease progression (when they were
not preceded by another disease progression criterion).
There were no surgical interventions, and eight subjectsreceived RT (seven in the placebo group, one in the
dutasteride group). Most subjects who required rescue
therapy received drug treatment (22 in the placebo group,
10 in the dutasteride group), usually antiandrogens or
luteinising hormone-releasing hormone analogues.
Significantlymore patients in the dutasteride group than
in the placebo group demonstrated a treatment response at
month 12 (70% [87 of 124] vs 12% [13 of 110]; p < 0.001)
and month 24 (56% [62 of 110] vs 8% [6 of 76]; p < 0.001).
[(Fig._3)TD$FIG]
Fig. 3 – Kaplan-Meier estimates of time to disease progression (intention-to-treat population).
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placebo group compared with the dutasteride group (88%
[127 of 144] vs 49% [72 of 146]; p < 0.001). The overall RR
reduction estimate in favour of dutasteridewas 71.63% (95%
CI, 61.69–79.00). The incidence of PSA progression was
numerically higher in the placebo group than in the
dutasteride group, although the difference was not statisti-
cally significant (17% [25 of 144] vs 13% [19 of 146];
p = 0.15).
3.4. Safety assessments
The incidence of AEs, serious AEs, AEs leading to study
discontinuation or withdrawal, and fatal AEs were similar
between the treatment groups (Table 6). No fatal AE wasTable 4 – Reasons for disease progression in intention-to-treat
populationa
Placebo
(n = 144)
Dutasteride
0.5 mg (n = 146)
Disease progressionb, no. (%) 49 (34) 25 (17)
PSADT 3 mo, no. 7 5
Absolute PSA high, no. 22 17
Rescue therapy, no. 16 4
Clinical progression
(positive biopsy), no.
1 0
Bone metastasesc, no. 5 2
ITT = intention to treat; PSA = prostate-specific antigen; PSADT = prostate-
specific antigen doubling time.
a Includes ITT subjects who had at least one postbaseline PSA measurement.
b Defined as the first time one of the above disease-progression criteria was
met during the study. If a subject met more than one disease-progression
criterion on the same date, he was counted in each one.
c Nine subjects in the placebo group and four in the dutasteride group had
bone metastases; four and two of these cases, respectively, were preceded by
another disease progression criterion.considered to be related to study treatment. The most
common AEs (occurring in 5% of patients in either
treatment group; data not shown) were nasopharyngitis,
urinary incontinence, gynaecomastia, hypertension, and
back pain.
Breast disorders were more common among subjects in
the dutasteride group (n = 10) than in the placebo group
(n = 4). Sexual AEs occurred in few subjects and were less
common in the dutasteride group than in the placebo group
(Table 6).
Cardiovascular AEs of special interest were reported in
four subjects in each treatment group (Table 6). One cardiac
failure AE occurred in the dutasteride group 391 d after
treatment initiation, which was considered by the investi-
gator to be unrelated to study treatment and possiblyTable 5 – Interventions for prostate cancer during the study
(intention-to-treat population)
Interventionsa Placebo,
no.
Dutasteride
0.5 mg, no.
Surgical intervention 0 0
Nonsurgical intervention 29 11
First nonsurgical intervention
Drug therapy 22 10
External beam radiation 7 1
HT used on or after first
nonsurgical intervention
23 10
Bicalutamide 15 9
Buserelin 0 1
Goserelin 2 1
Flutamide 4 0
Leuprorelin 3 0
Leuprorelin acetate 8 3
HT = hormone therapy.
a Some of these interventions were preceded by another criterion of
disease progression and so would not have counted as a disease progression
criterion for a subject.
Table 6 – Adverse events starting after initiation of study
treatment in the intention-to-treat population
Placebo
(n = 147)
Dutasteride
0.5 mg (n = 147)
Adverse events, no. (%)
Any event 95 (65) 97 (66)
Any serious event 16 (11) 16 (11)
Drug-related event 15 (10) 10 (7)
Event leading to withdrawal
from the study
5 (3) 5 (3)
Fatal event 2 (1) 2 (1)
Events related to sexual function, no. (%)
Impotence 6 (4) 0
Altered (decreased) libido 4 (3) 1 (1)
Breast disorders, no. (%) 4 (3) 10 (7)
Cardiovascular events, no. (%)
Any event 4 (2.7) 4 (2.7)
Acute coronary syndrome 1 (0.7) 1 (0.7)
Ischaemic coronary artery disorders
or atherosclerosis
1 (0.7) 1 (0.7)
Ischaemic cerebrovascular events 1 (0.7) 1 (0.7)
Cardiac failure 0 1 (0.7)
Cardiac arrhythmias 1 (0.7) 0
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Dutasteride treatment was continued and the event
resolved with specific treatment. In contrast, AEs in the
cardiac disorders system organ class (SOC) were more
common in the dutasteride group (n = 10) than in the
placebo group (n = 4). No individual AE in this SOC was
reported by more than one subject in either treatment
group, with the exception of atrial fibrillation (two subjects
in the dutasteride group, one subject in the placebo group).
4. Discussion
Dutasteride treatment over 2 yr significantly delayed the
doubling time for PSA in men with biochemical failure
following radical therapy for PCa. Baseline PSA, baseline
PSADT, Gleason score and tumour stage at PCa diagnosis,
the type of radical therapy received, HT use before
screening, and time from radical therapy to screening were
all significant predictors of time to PSA doubling. The RR
reduction in favour of dutasteride was similar in a model
with or without these predictors (70% and 66%, respective-
ly), indicating that subjects in this setting may benefit from
dutasteride treatment regardless of baseline characteristics.
Secondary efficacy end points reinforced the primary
efficacy findings. Dutasteride delayed PCa progression,
affecting both PSA-related end points and clinical outcomes
(need for rescue therapy and the incidence of bone
metastases). The observation that bone metastases devel-
oped in fewer patients receiving dutasteride than placebo is
of interest; however, the actual number of patients affected
was small, and a properly powered, prospective study is
needed to confirm this finding.
Subgroup analyses according to previous therapy were
generally supportive of the results for the overall study
population. These analyses should, however, be inter-
preted with caution given the relatively small sample sizes
and the lack of adjustment for multiple end points. Results
of other subgroup analyses of interest, including baselinePSADT, were also consistent with those for the overall
population.
The primary end point selected for ARTS was time to PSA
doubling from start of randomised treatment. Selection of a
PSA-related end point is clinically less meaningful than
harder end points such as biopsy-confirmed progression in
clinical stage or metastases confirmed by bone scan, and
may also have resulted in inherent bias in favour of
dutasteride given the effect of treatment on PSA levels.
Nevertheless, a serial rise in PSA levels after radical therapy
typically predates clinically or radiographically detectable
metastatic disease by many years [3], and the population
with rising PSA levels represents the second-largest group
of patients with PCa [8]. Changes in PSADT may represent a
more sensitive end point to detect biological activity than
traditional PSA response criteria. For example, inmenwith a
rising PSA level after RP, a median PSADT <10 mo is the
most significant predictor for progression to metastatic
disease [3]. Similarly, a short PSADT following RT is
predictive of progression to metastatic disease [9,10].
Dutasteride had predictable and manageable side effects
in the study population. The incidence of sexual AEs among
men treated with dutasteride was lower than might be
expected from the previous safety profile of the drug [11].
However, it is consistent with the impaired sexual function
among a substantial proportion of the study population.
Treatment options in men with biochemical progression
after radical therapy are limited; therefore, a treatment
with limited side effects that delays PSA progression and
progression to clinical signs and symptoms could be a useful
therapeutic option. Previous studies have investigated
agents such as exisulind, rosiglitazone, celecoxib, dietary
supplements, and adecatumumab [12–16]. While some of
these studies reported encouraging results [12,15], no
useful therapies have emerged. The only previous random-
ised study of a 5a-reductase inhibitor (5-ARI) after RP
compared 12 mo of treatment with finasteride and placebo
in 120 men with serum PSA levels of 0.6–10.0 ng/ml, no
evidence of skeletal metastasis, and no previous ADT [17].
Finasteride delayed the increase in PSA by approximately
9 mo compared with placebo. There were also fewer
recurrences in the finasteride group, although the differ-
ence compared with the placebo group was not statistically
significant. In the present study, dutasteride (a dual 5-ARI)
resulted in reductions in both PSA-related progression
events and also clinical-related outcomes. Nevertheless,
additional data would be helpful in deciding if 5-ARIs could
be considered a treatment option in this setting.
A potential concern about using 5-ARIs to treat PCa is
that they may shorten the time to development of disease
that is resistant to ADT [18]. Despite 5-ARIs being in clinical
use for>10 yr and the subject of long-term clinical trials, no
such association has yet been reported. However, longer-
term follow-up is necessary before this concern can be fully
disregarded.
A PSADT of <9 mo has been proposed as a cut-off point
conferring an increased risk of PCa death and reduced
overall survival [19–21]. In ARTS, a cut-off of 12 mo was
predefined for the efficacy analyses. Among subjects with a
E U RO P E AN URO LOG Y 6 3 ( 2 0 1 3 ) 7 7 9 – 7 8 7786baseline PSADT of <12 mo, and therefore at theoretically
higher risk of PCa-related outcomes, a smaller proportion of
the dutasteride group experienced a PSA-doubling event
than the placebo group (34% vs 62%). However, based on
previous studies [22,23], the relatively short follow-upperiod
of ARTS is insufficient to confirm if the impact of dutasteride
treatment on PSADT translates into overall or PCa-specific
survival; this represents a limitation of the study.
Another potential limitation of the study is that
investigators and patients were not blinded to PSA test
results. Knowledge of PSA level could potentially unblind
the study and influence investigators’ decisions such as
timing of rescue therapy. Revealing PSA values was
necessary, however, for investigators to manage their
patients and also to explore the impact of the disease
and treatment on patient-reported health outcomes (data
not shown). Despite this potential limitation, results were
consistently in favour of dutasteride across end points,
including non-PSA variables such as need for rescue therapy
or development of bone metastases.
There was a substantial difference in median follow-up
time between the two treatment groups (722 d for the
dutasteride group vs 456 d for the placebo group). This is
most likely due to the higher withdrawal rate in the placebo
group than in the dutasteride group, which, in turn, was
driven by withdrawal due to disease progression and
investigator/patient decision to withdraw. Withdrawal due
to disease progression was based on objective, predefined
criteria, indicating a benefit of dutasteride treatment over
placebo. Investigator or patient decisions to withdraw may
have been more subjective, and potentially influenced by
the PSA unblinding.
5. Conclusions
Dutasteride delayed the biochemical progression of PCa in
patients with biochemical failure after radical therapy for
clinically localised disease. The safety and tolerability profile
of dutasteride in this patient population was generally
consistent with previous experience with no new safety
signals identified. A larger-scale study with a longer follow-
up period is needed to determinewhether delayed biochem-
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